Berikutnya

Putar otomatis

Peptide Receptor Radionuclide Therapy (PRRT)

3 Tampilan • 07/09/23
Membagikan
Menanamkan
administrator
administrator
Pelanggan
0

One of the most significant treatment options for neuroendocrine cancer patients became available with the 2018 FDA approval of Lutathera®, the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT).

NET experts Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Erik Mittra and Dr.
Jonathan Strosberg describe the treatment, how it works, and the benefits for patients.

What do physicians look forward to in the future for PRRT?

Menampilkan lebih banyak
0 Komentar sort Sortir dengan
Komentar Facebook

Berikutnya

Putar otomatis